Inhibition of Tumor Growth Using Salmonella Expressing Fas Ligand
暂无分享,去创建一个
[1] John Calvin Reed,et al. Attenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growth , 2007, Proceedings of the National Academy of Sciences.
[2] M. Loeffler,et al. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. , 2006, The Journal of clinical investigation.
[3] A. Yahagi,et al. Fas Ligand Induces Cell-Autonomous IL-23 Production in Dendritic Cells, a Mechanism for Fas Ligand-Induced IL-17 Production1 , 2005, The Journal of Immunology.
[4] M. Sznol,et al. Systemic Administration of an Attenuated, Tumor-Targeting Salmonella typhimurium to Dogs with Spontaneous Neoplasia: Phase I Evaluation , 2005, Clinical Cancer Research.
[5] A. Thorburn,et al. Death receptor-induced cell killing. , 2004, Cellular signalling.
[6] O. Janssen,et al. Slowly getting a clue on CD95 ligand biology. , 2003, Biochemical pharmacology.
[7] S. Rosenberg,et al. Antitumor Effects in Mice of the Intravenous Injection of Attenuated Salmonella Typhimurium , 2002, Journal of immunotherapy.
[8] Hans Wolf-Watz,et al. Molecular characterization of type III secretion signals via analysis of synthetic N‐terminal amino acid sequences , 2002, Molecular microbiology.
[9] J. Tschopp,et al. FAS Engagement Induces the Maturation of Dendritic Cells (Dcs), the Release of Interleukin (Il)-1β, and the Production of Interferon γ in the Absence of IL-12 during Dc–T Cell Cognate Interaction , 2000, The Journal of experimental medicine.
[10] P. Fink,et al. Fas Ligand Costimulates the In Vivo Proliferation of CD8+ T Cells1 , 2000, The Journal of Immunology.
[11] X. Luo,et al. Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium. , 2000, The Journal of infectious diseases.
[12] M. Levine,et al. Optimization of Plasmid Maintenance in the Attenuated Live Vector Vaccine Strain Salmonella typhiCVD 908-htrA , 1999, Infection and Immunity.
[13] F. Dallegri,et al. Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes. , 1999, Journal of immunology.
[14] E. Nabel,et al. Gene transfer of Fas ligand induces tumor regression in vivo. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[15] H. Maeda,et al. Polymorphism of murine Fas ligand that affects the biological activity. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[16] M. Weller,et al. Local Fas/APO‐1 (CD95) ligand‐mediated tumor cell killing in vivo , 1995, European journal of immunology.
[17] T. Malek,et al. Selective expression of Ly-6G on myeloid lineage cells in mouse bone marrow. RB6-8C5 mAb to granulocyte-differentiation antigen (Gr-1) detects members of the Ly-6 family. , 1993, Journal of immunology.
[18] S. Nagata,et al. Lethal effect of the anti-Fas antibody in mice , 1993, Nature.
[19] G. Dougan,et al. Expression of human IL-1 beta in Salmonella typhimurium. A model system for the delivery of recombinant therapeutic proteins in vivo. , 1992, Journal of immunology.
[20] D. Euhus,et al. Tumor measurement in the nude mouse , 1986, Journal of surgical oncology.
[21] Bill Broyles. Notes , 1907, The Classical Review.
[22] John Mao,et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.